Skip to content

Memantine for epilepsy in children

Evaluation of efficacy of add on oral memantine in children with developmental epileptic encephalopathy aged 2-14 years: a randomized controlled trial - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/102322
Enrollment
80
Registered
2026-01-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G408- Other epilepsy and recurrent seizures

Interventions

Intervention1: Memantine: 2-5-5 mg/day for children 6 years or younger and 5-10 mg/day for children older than 6 years in the form of oral tablets daily in one to two divided doses for eight weeks, al

Sponsors

Dr Vaibhav Kashyap
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children with developmental and epileptic encephalopathy

Exclusion criteria

Exclusion criteria: 1.History of allergy to memantine 2.Already using or used memantine previously 3.Parents not providing informed consent 4.Clinical evidence of any other major systemic illness

Design outcomes

Primary

MeasureTime frame
Number of participants with a favourable responseTimepoint: 8 weeks

Secondary

MeasureTime frame
Number of participants with improvement in EEGTimepoint: At 8 weeks;Number of participants achieving at least a 50 percent reduction in seizure frequency Timepoint: At 8 weeks;Parent Global Impression Improvement scoreTimepoint: At 8 weeks;Change in social quotientTimepoint: At baseline (0 week) and 8 weeks

Countries

India

Contacts

Public ContactDr Vaibhav Kashyap

All India Institute of Medical Sciences, Rishikesh

drprateekpanda@gmail.com9650149735

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026